<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1015</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2025-20-1-154-164</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>SUPPORTIVE THERAPY ASPECTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>АСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects</article-title><trans-title-group xml:lang="ru"><trans-title>Бортезомибиндуцированная периферическая полинейропатия у больных множественной миеломой: болевой синдром и психопатологические аспекты</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2013-9507</contrib-id><name-alternatives><name xml:lang="en"><surname>Irugova</surname><given-names>E. Z.</given-names></name><name xml:lang="ru"><surname>Иругова</surname><given-names>Э. З.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Elmira Zalimkhanovna Irugova</p><p>125167; 4 Novyy Zykovskiy Proezd; Moscow</p></bio><bio xml:lang="ru"><p>Эльмира Залимхановна Иругова</p><p>125167; Новый Зыковский пр-д, 4; Москва</p></bio><email>irugova.e@blood.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4966-8146</contrib-id><name-alternatives><name xml:lang="en"><surname>Mendeleeva</surname><given-names>L. P.</given-names></name><name xml:lang="ru"><surname>Менделеева</surname><given-names>Л. П.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125167; 4 Novyy Zykovskiy Proezd; Moscow</p></bio><bio xml:lang="ru"><p>125167; Новый Зыковский пр-д, 4; Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7506-4947</contrib-id><name-alternatives><name xml:lang="en"><surname>Vybornykh</surname><given-names>D. E.</given-names></name><name xml:lang="ru"><surname>Выборных</surname><given-names>Д. Э.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125167; 4 Novyy Zykovskiy Proezd; Moscow</p></bio><bio xml:lang="ru"><p>125167; Новый Зыковский пр-д, 4; Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4142-171X</contrib-id><name-alternatives><name xml:lang="en"><surname>Soloveva</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Соловьева</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125167; 4 Novyy Zykovskiy Proezd; Moscow</p></bio><bio xml:lang="ru"><p>125167; Новый Зыковский пр-д, 4; Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8239-5442</contrib-id><name-alternatives><name xml:lang="en"><surname>Fedorova</surname><given-names>S. Yu.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>С. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125167; 4 Novyy Zykovskiy Proezd; Moscow</p></bio><bio xml:lang="ru"><p>125167; Новый Зыковский пр-д, 4; Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7944-6202</contrib-id><name-alternatives><name xml:lang="en"><surname>Solovev</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Соловьев</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>125167; 4 Novyy Zykovskiy Proezd; Moscow</p></bio><bio xml:lang="ru"><p>125167; Новый Зыковский пр-д, 4; Москва</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Center for Hematology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-03-19" publication-format="electronic"><day>19</day><month>03</month><year>2025</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>154</fpage><lpage>164</lpage><history><date date-type="received" iso-8601-date="2025-03-22"><day>22</day><month>03</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-03-22"><day>22</day><month>03</month><year>2025</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/1015">https://oncohematology.abvpress.ru/ongm/article/view/1015</self-uri><abstract xml:lang="en"><p><bold>   Background. </bold>One of the most common causes of peripheral neuropathy in multiple myeloma patients is bortezomib‑induced peripheral neuropathy (bIpN), which is clinically characterized by paresthesia, a burning sensation, numbness, and primarily pain in the limbs. This pain syndrome is often associated with the development of anxiety and depression.</p><p><bold>   Aim. </bold>To study the pain syndrome associated with BIPN and determine the relationship between mental disorders and pain descriptors in patients with multiple myeloma at the completion stage of induction therapy and after autologous hematopoietic stem cell transplantation (auto‑HSCT).</p><p><bold>   Materials and methods. </bold>From January 2023 to April 2024 a prospective study was conducted to examine pain and its relationship with psychopathological manifestations. The study included 48 patients (38 women and 10 men, median age 54 years) with multiple myeloma and diagnosed bIpN. pain syndrome and psychometric indicators were assessed using various validated algometric and psychometric techniques during hospitalization before auto‑HSCT and on day 100 after transplantation. Electroneuromyography was performed at the same time for an objective assessment of the studied parameters.</p><p><bold>   Results.</bold> BIPN was diagnosed in 32 % of patients. pain intensity ranged from minimal to unbearable, With higher BIPN severity correlating with more vivid and diverse descriptions of the pain syndrome. pain localized in the fingers and toes predominated in 58 % of patients. The use of the pain detect questionnaire and the visual Analog Scale allowed for a detailed evaluation of changes in pain syndrome, revealing a statistically significant reduction in pain intensity 100 days after auto‑HSCT (p &lt; 0.05). A control electroneuromyography conducted 100 days after auto‑HSCT confirmedpartial or complete restoration of nerve fibers functional state. Based on the beck Anxiety and depression Inventory questionnaires completed by patients with pronounced pain syndrome, anxiety symptoms were identified in 6 cases (18 %), and depressive states in 8 cases (24 %). A study of patients’ psycho‑emotional states 100 days after auto‑HSCT showed a reduction in the frequency and severity of depressive states. However, unlike depression, anxiety persisted in the same patients.</p><p><bold>   Conclusion.</bold> The conducted study, which testifies to the presence and persistence of psychoemotional disorders in a number of patients, indicates the need for a comprehensive approach to treatment, including not only pain therapy, but also psychoemotional support.</p></abstract><trans-abstract xml:lang="ru"><p><bold>   Введение. </bold>Одна из наиболее частых причин развития периферической полинейропатии у больных множественной миеломой – бортезом-ибиндуцированная полинейропатия (БИПН), клинически характеризующаяся парестезиями, ощущением жжения и онемения и главным образом болью в конечностях. Болевой синдром при этом зачастую сопряжен с развитием тревоги и депрессивного состояния.</p><p><bold>   Цель исследования</bold> – изучить болевой синдром, ассоциированный с БИПН, а также определить взаимосвязь психических расстройств и дескрипторов боли у пациентов с множественной миеломой на этапе завершения индукционной терапии и после аутологичной трансплантации гемопоэтических стволовых клеток (ауто‑ТГСК).</p><p><bold>   Материалы и методы. </bold>С января 2023 г. по апрель 2024 г. в проспективное исследование для изучения боли и взаимосвязи между ней и психопатологическими проявлениями включены 48 пациентов (38 женщин и 10 мужчин, медиана возраста 54 года) с множественной миеломой и диагностированной БИПН. Оценку болевого синдрома и психометрических показателей с использованием различных валидизированных альгометрических и психометрических методов проводили при госпитализации перед выполнением ауто‑ТГСК и на 100‑й день после нее. Для объективной оценки изучаемых параметров в эти же сроки выполняли электронейромиографическое исследование.</p><p><bold>   Результаты. </bold>БИПН диагностирована у 32 % пациентов. Уровень интенсивности боли варьировал от минимальной до невыносимой. У 58 % пациентов преобладали боли, локализующиеся в области пальцев рук и ног. Использование шкалы pain detect и визуально‑аналоговой шкалы позволило детально оценить изменение болевого синдрома и показать статистически значимое снижение интенсивности боли спустя 100 дней после ауто‑ТГСК (p &lt; 0,05). Результаты контрольного электронейромиографического исследования, выполненного через 100 дней после ауто‑ТГСК, подтверждали частичное или полное восстановление функционального состояния нервных волокон. На основании данных опросников тревоги и депрессии Бека, заполненных пациентами на фоне развернутого болевого синдрома, симптомы тревоги выявлены в 6 (18 %) случаях, а депрессивные состояния – в 8 (24 %). При исследовании психоэмоционального состояния больных через 100 дней после ауто‑ТГСК выявлено снижение частоты и глубины депрессивного состояния. Однако в отличие от депрессии тревожное состояние сохранялось у тех же больных.</p><p><bold>   Заключение. </bold>Результаты проведенного исследования свидетельствуют о присутствии и сохранении у ряда пациентов психоэмоциональных расстройств и указывают на необходимость комплексного подхода к лечению, включающего не только терапию боли, но и психоэмоциональную поддержку.</p></trans-abstract><kwd-group xml:lang="en"><kwd>multiple myeloma</kwd><kwd>bortezomib‑induced peripheral neuropathy</kwd><kwd>pain syndrome</kwd><kwd>pain detect questionnaire</kwd><kwd>McGill pain questionnaire</kwd><kwd>pain catastrophizing scale</kwd><kwd>brief psychiatric rating scale</kwd><kwd>depression</kwd><kwd>anxiety</kwd><kwd>electroneuromyographic examination</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>множественная миелома</kwd><kwd>бортезомибиндуцированная периферическая полинейропатия</kwd><kwd>болевой синдром</kwd><kwd>опросник pain detect</kwd><kwd>опросник боли Мак‑Гилла</kwd><kwd>шкала катастрофизации боли</kwd><kwd>краткая психиатрическая оценочная шкала</kwd><kwd>депрессия</kwd><kwd>тревога</kwd><kwd>электронейромиографическое исследование</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was performed without external funding</funding-statement><funding-statement xml:lang="ru">Исследование проведено без спонсорской поддержки</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Delforge M., Bladé J., Dimopoulos M.A. et al. Treatment­related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11(11):1086–95. DOI: 10.1016/S1470­2045(10)70068­1</mixed-citation></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Belyakov K.M., Gustov A.V. Paraneoplastic polyneuropathies. Nizhniy Novgorod: NGMA, 2007. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Беляков К.М., Густов А.В. Паранеопластические полиневропатии. Н. Новгород: НГМА, 2007.</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><mixed-citation>Corthals S.L., Kuiper R., Johnson D.C. et al. Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011;96(11):1728–32. DOI: 10.3324/haematol.2011.041434</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Leone C., Federico V., La Cesa S. et al. An observational study assessing peripheral neuropathy related to multiple myeloma. Neurol Sci 2016;37(7):1141–3. DOI: 10.1007/s10072­016­2542­9</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Ballegaard M., Nelson L.M., Gimsing P. Comparing neuropathy in multiple myeloma and AL amyloidosis. J Peripher Nerv Syst 2021;26(1):75–82. DOI: 10.1111/jns.12428</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Richardson P.G., Delforge M., Beksac M. et al. Management of treatment­emergent peripheral neuropathy in multiple myeloma. Leukemia 2012;26(4):595–608. DOI: 10.1038/leu.2011.346</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Shao L., Wang S., Meng H. et al. [Bortezomib­induced peripheral neuropathy in multiple myeloma patients]. Zhonghua Yi Xue Za Zhi 2015;95(40):3297–301. (In Chinese).</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lee S.E., Choi K., Han S. et al. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib­containing therapy. Anticancer Drugs 2017;28(6):660–8. DOI: 10.1097/CAD.0000000000000506</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Minarik J., Pavlicek P., Pour L. et al. Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy. PLoS One 2015;10(4):e0123866. DOI: 10.1371/journal.pone.0123866</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wang H., Wang L., Lu Y. et al. Long­term outcomes of different bortezomib­based regimens in Chinese myeloma patients. Onco Targets Ther 2016;9:587–95. DOI: 10.2147/OTT.S97457</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>García­Sanz R., Corchete L.A., Alcoceba M. et al. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. Hematol Oncol 2017;35(4):746–51. DOI: 10.1002/hon.2337</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Windebank A.J., Grisold W. Chemotherapy­induced neuropathy. J Peripher Nerv Syst 2008;13(1):27–46. DOI: 10.1111/j.1529­8027.2008.00156.x</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Vaxman I., Mauerman M.L., Gatt M.L. et al. Foot drop in patients treated with bortezomib – a case series and review of the literature. Leuk Lymphoma 2022;63(3):722–8. DOI: 10.1080/10428194.2021.1992758</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-­induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008;112(5):1593–9. DOI: 10.1182/blood­2008­04­149385</mixed-citation></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Semochkin S.V., Solovyev M.V., Mendeleeva L.P. Prevention and management of bortezomib-­induced peripheral neuropathy in patients with multiple myeloma. Onkogematologiya = Oncohematology 2022;17(2):141–50. (In Russ.). DOI: 10.17650/1818­8346­2022­17­2­141­150</mixed-citation><mixed-citation xml:lang="ru">Семочкин С.В., Соловьев М.В., Менделеева Л.П. Профилактика и лечение бортезомиб-индуцированной нейропатии у пациентов с множественной миеломой. Онкогематология 2022;17(2):141–50. DOI: 10.17650/1818­8346­2022­17­2­141­150</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><mixed-citation>Bechakra M., Nieuwenhoff M.D., van Rosmalen J. et al. Clinical, electrophysiological, and cutaneous innervation changes in patients with bortezomib­induced peripheral neuropathy reveal insight into mechanisms of neuropathic pain. Mol Pain 2018;14:1744806918797042. DOI: 10.1177/1744806918797042</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). 2017.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Badros A., Goloubeva O., Dalal J.S. et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single­center experience and review of the literature. Cancer 2007;110(5):1042–9. DOI: 10.1002/cncr.22921</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Richardson P.G., Briemberg H., Jagannath S. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113–20. DOI: 10.1200/JCO.2005.04.777</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Broyl A., Corthals S.L., Jongen J.L. et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON­65/GMMG­HD4 trial. Lancet Oncol 2010;11(11):1057–65. DOI: 10.1016/S1470­2045(10)70206­0</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Mateos M.V., Dimopoulos M.A., Cavo M. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378(6):518–28. DOI: 10.1056/NEJMoa1714678</mixed-citation></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Solovev M.V., Soloveva M.V., Mendeleeva L.P. Supportive therapy in multiple myeloma: practical recommendations. Klinicheskaya onkogematologiya = Clinical Oncohematology 2023;16(4):426–48. (In Russ.). DOI: 10.21320/2500­2139­2023­16­4­426­448</mixed-citation><mixed-citation xml:lang="ru">Соловьев М.В., Соловьева М.В., Менделеева Л.П. Сопроводительная терапия при множественной миеломе: практические рекомендации. Клиническая онкогематология 2023;16(4): 426–48. DOI: 10.21320/2500­2139­2023­16­4­426­448</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><mixed-citation>Morawska M., Grzasko N., Kostyra M. et al. Therapy-­related peripheral neuropathy in multiple myeloma patients. Hematol Oncol 2015;33(4):113–9. DOI: 10.1002/hon.2149</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Guzdar A., Costello C. Supportive care in multiple myeloma. Curr Hematol Malig Rep 2020;15(2):56–61. DOI: 10.1007/s11899­020­00570­9</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Li Y., Lustberg M.B., Hu S. Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy­induced peripheral neuropathy. Cancers (Basel) 2021;13(4):766. DOI: 10.3390/cancers13040766</mixed-citation></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Zyrina G.V., Slyusar T.A. Clinical and psychological features of pain syndrome in multiple myeloma. Meditsinskiy alfavit = Medical Alphabet 2020;(22):26–9. (In Russ.). DOI: 10.33667/2078­5631­2020­22­26­29</mixed-citation><mixed-citation xml:lang="ru">Зырина Г.В., Слюсарь Т.А. Клинико­-психологические особен­ности болевого синдрома при множественной миеломе. Медицинский алфавит 2020;(22):26–9. DOI: 10.33667/2078­5631­2020­22­26­29</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><mixed-citation>Selvy M., Kerckhove N., Pereira B. et al. Prevalence of chemotherapy­induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross­sectional study. Front Pharmacol 2021;12:637593. DOI: 10.3389/fphar.2021.637593</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Azoulay D., Giryes S., Nasser R. et al. Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain­derived neurotropic factor protein levels and a gene polymorphism. J Clin Neurol 2019;15(4):511–6. DOI: 10.3988/jcn.2019.15.4.511</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Beijers A.J., Vreugdenhil G., Oerlemans S. et al. Chemotherapy­-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support Care Cancer 2016;24(6):2411–20. DOI: 10.1007/s00520­015­3032­y</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Freynhagen R., Baron R., Gockel U. et al. Pain DETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22(10): 1911–20. DOI: 10.1185/030079906X132488</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1(3):277–99. DOI: 10.1016/0304­3959(75)90044­5</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Sullivan M.J.L., Bishop S.R., Pivik J. The pain catastrophizing scale: development and validation. Psychological Assessment 1995;7(4):524–32. DOI: 10.1037/1040­3590.7.4.524</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Nicholson I.R., Chapman J.E., Neufeld R.W. Variability in BPRS definitions of positive and negative symptoms. Schizophr Res 1995;17(2):177–85. DOI: 10.1016/0920­9964(94)00088­P</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988;56(6):893–7. DOI: 10.1037/0022­006X.56.6.893</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Beck A.T., Ward C.H., Mendelson M. et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–71. DOI: 10.1001/archpsyc.1961.01710120031004</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Heeringa S.G., West B.T., Berglund P.A. et al. Applied survey data analysis. 2<sup/> edn. 2017. Chapman and Hall/CRC. DOI: 10.1201/9781315153278</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Palumbo A., Rajkumar S.V., San Miguel J.F. et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem­cell transplantation. J Clin Oncol 2014;32(6):587–600. DOI: 10.1200/JCO.2013.48.7934</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Yang Y., Zhao B., Lan H. et al. Bortezomib­induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach. Crit Rev Oncol Hematol 2024;197:104353. DOI: 10.1016/j.critrevonc.2024.104353</mixed-citation></ref></ref-list></back></article>
